The U.S. point-of-care molecular diagnostics market size was valued at USD 4.90 billion in 2023 and is anticipated to reach around USD 5.86 billion by 2033, growing at a CAGR of 1.8 % from 2024 to 2033.
The U.S. point-of-care molecular diagnostics market size was valued at USD 4.90 billion in 2023 and is anticipated to reach around USD 5.86 billion by 2033, growing at a CAGR of 1.8 % from 2024 to 2033.
Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.novaoneadvisor.com/report/sample/8417
The growth of the market is driven by rise in end-user awareness, along with the increased efficiency of the testing methods and favourability for non-laboratory testing. For instance, in the U.S., approximately 1% infants are diagnosed with congenital heart diseases (CHDs) every year. However, advancements in prenatal testing have led to rapid detection of genetic biomarkers in embryos, thus leading to early diagnosis of CHDs and other genetic disorders.
The U.S. point-of-care molecular diagnostics market growth is positively impacted by the county’s patient-centric healthcare services. Thus, the demand for POC diagnostics has led to significant market growth. According to a study in the BioChip Journal in 2021, pathogen-specific treatment provided by multiplex POC tests is crucial in remote critical care, thus witnessing increased adoption in laboratory facilities. The applications of POC molecular testing range from glucose tests to complex coagulation testing. Due to the easy accessibility and reduced timeframe of diagnosis, many clinics are opting for POC testing, as opposed to conventional testing methods.
The increasing incidence of genetic disorders as well as infectious diseases, such as sexually transmitted diseases (STIs, namely HIV, HPV) and dengue, have led to fastened technological developments in molecular diagnostics. Moreover, the introduction of healthcare information systems, paired with the advent of teleconsultation services, has led to increased awareness and adoption of POC testing. The increase in
Key Takeaways:
- The OTC segment held a marginally higher share of 52.09% in the U.S, and is anticipated to register a significant growth rate from 2024 to 2033.
- The point-of-care test location segment is estimated to register the fastest CAGR over the forecast period.
- The infectious diseases segment registered a market share of 31.17% in 2023.
- The other applications segment held the largest market share of over 50.9% in 2023
- The oncology segment is anticipated to witness the fastest growth over the forecast period.
- The PCR-based segment dominated the market with a revenue share of 65.67% in 2023.
- The genetic sequencing-based POC molecular diagnostics segment is anticipated to register the fastest CAGR during the forecast period
- The decentralized segment held the largest market share of 42.86% in 2023
- The home care segment is expected to grow at the fastest rate over the forecast period.
What are the Importance of Point-of-Care Molecular Diagnostics Market?
- Rapid Results: Point-of-care molecular diagnostics enable healthcare providers to obtain test results within minutes to hours, compared to traditional lab-based testing which can take days. This rapid turnaround time is crucial for timely diagnosis and treatment initiation, especially in critical conditions.
- Improved Patient Outcomes: Faster diagnosis and treatment decisions lead to improved patient outcomes by reducing the time to appropriate therapy. In conditions such as infectious diseases or cancer, early detection can significantly enhance prognosis and survival rates.
- Reduced Healthcare Costs: Point-of-care molecular diagnostics can potentially lower healthcare costs by reducing the need for multiple clinic visits and hospitalizations. Timely diagnosis and targeted therapy also minimize unnecessary treatments, hospital stays, and associated expenses.
- Enhanced Public Health Response: During outbreaks or pandemics, such as COVID-19, rapid testing at the point of care is essential for early detection, containment, and mitigation strategies. Point-of-care molecular diagnostics play a critical role in monitoring and controlling the spread of infectious diseases within communities.
- Remote and Resource-Limited Settings: Point-of-care testing is particularly valuable in remote or resource-limited settings where access to centralized laboratories is limited. These technologies enable healthcare providers to deliver diagnostic services in underserved areas, improving healthcare equity and access.
- Personalized Medicine: Molecular diagnostics provide insights into an individual’s genetic makeup, allowing for personalized treatment strategies tailored to their specific genetic profile. Point-of-care molecular tests facilitate the integration of personalized medicine into routine clinical practice, optimizing therapeutic outcomes.
- Point-of-Care Decision Making: By bringing testing closer to the patient, healthcare providers can make informed decisions at the point of care, leading to more efficient management of chronic conditions, better medication management, and timely interventions to prevent disease progression.
- Streamlined Workflow: Integration of point-of-care molecular diagnostics into clinical workflows streamlines the testing process, reducing turnaround times, minimizing errors associated with sample transport, and enhancing overall efficiency in healthcare delivery.
In conclusion, the Point-of-Care Molecular Diagnostics Market represents a significant advancement in healthcare technology, offering numerous benefits including rapid results, improved patient outcomes, cost savings, enhanced public health response, increased accessibility, personalized medicine, and streamlined workflow, all contributing to the transformation of healthcare delivery.
Immediate Delivery Available, Get Full Access@
https://www.novaoneadvisor.com/report/checkout/8417
Test Location Insights
The OTC segment held a marginally higher share of 52.09% in the U.S, and is anticipated to register a significant growth rate from 2024 to 2033. Self-testing and over-the-counter testing kits are widely available on e-commerce platforms and facilitate early diagnosis, along with constant patient monitoring. The distinctive factor for OTC tests remains their availability without the need of a prescription, and are thus applicable for more common usage. Instances of product development in the segment are spurring market growth further.
The point-of-care test location segment is estimated to register the fastest CAGR over the forecast period. POC molecular testing identifies viruses and infectious agents using their genetic material, and is thus marketed as a POC test kit that can provide quick results and portability. POC tests for various cancers, including prostate, bladder, colorectal, cervical, HPV-causing head and neck, liver, breast, and lung cancer are also commercially available in the U.S. The growing interest in developing molecular diagnostic platforms is driving market participants to design assays & molecular diagnostic systems for near-patient testing. For instance, in October 2023, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) at the National Institutes of Health (NIH) awarded the Atlanta Center for Microsystems Engineered Point-of-Care Technologies (ACME POCT) with USD 7.8 million over the next 5 years to support inventors across the U.S.
Application Type Insights
The infectious diseases segment registered a market share of 31.17% in 2023. In 2021, there were 36,136 new HIV diagnoses in the United States, with an estimated 1.2 million people living with HIV. Despite significant efforts in managing infectious diseases, there is a huge demand for low-cost, accurate, and sensitive POC products. Nanotechnology has found widespread applications in the healthcare industry.
The other applications segment held the largest market share of over 50.9% in 2023, owing to the rising awareness regarding the benefits associated with the adoption of POC molecular diagnostic solutions. This segment comprises POC solutions used in fertility & pregnancy testing, nephrology, autoimmune disease, and cardiac markers, among others. Due to the lack of medical intervention needed in these tests, significant growth is anticipated in the other applications segment over the forecast period.
The oncology segment is anticipated to witness the fastest growth over the forecast period. POC tests are being rapidly adopted for enabling mass screening & early detection for a broad range of cancer types. Furthermore, presence of a large number of government-funded testing programs, such as the National Breast and Cervical Cancer Early Detection Program, is expected to drive market growth.
Technology Insights
The PCR-based segment dominated the market with a revenue share of 65.67% in 2023. PCR is the foremost and simplest procedure performed before any molecular diagnostic investigation involving genetic material. This technology enables cancer detection in its early stages, often before clinical symptoms manifest. The increase in applications of POC molecular diagnostics in the fields of pharmacogenomics, drug discovery & development, acquired immunodeficiency syndrome, and cancer research directly boosts the demand for PCR technologies. PCR-based segment held a significant share due to the advantages and varied applications of multiplex PCR over conventional PCR methodologies.
The genetic sequencing-based POC molecular diagnostics segment is anticipated to register the fastest CAGR during the forecast period owing to the increasing demand for rapid and accurate testing and rising prevalence of infectious diseases. Furthermore, advancements in sequencing techniques have led to increased adoption in various medical settings, driving market expansion. Moreover, the growing demand for personalized medicine and expanding applications of genetic sequencing are driving the growth of this segment.
End-use Insights
The decentralized segment held the largest market share of 42.86% in 2023, owing to the wide applications of POC molecular diagnostics in decentralized labs. These tests have revolutionized the market by accelerating decision-making and reducing turnaround time for decentralized testing. Decentralized testing empowers healthcare providers by saving chain-lag time, saving costs, and reducing the length of delay in treatment. The usage of assays aids the rapid detection and automation of workflows in comprehensive tests, along with other advantages. In December 2023, Roche, a leading healthcare company in pharmaceuticals and diagnostics, announced a recent agreement to buy POC technology from LumiraDx for USD 350 million. With this movement, the company aims to use LumiraDx’s versatile platform in improving point-of-care testing in decentralized healthcare settings globally.
The home care segment is expected to grow at the fastest rate over the forecast period. A primary factor driving the home care segment is the improved patient care decision-making due to reduced diagnosis time. Moreover, it enables better patient care and provides faster access to treatment. The increase in geriatric population has led to a larger section of the population being vulnerable to chronic illnesses. Technological advancements have led to the introduction of novel devices for treatment that can be used in homecare settings. Thus, the increased access to medical care and focus on better technological solutions in home care testing is burgeoning the market growth.
Recent Developments
- In February 2024, BD, a U.S. based medical technology company, announced that they have begun clinical trials for a rapid Point-of Care Molecular Dx instrument and an assay to detect STIs.
- In November 2023, binx health, a healthcare technology and diagnostics company, announced its agreement with Fisher Healthcare, a part of Thermo Fisher Scientific, to expand the nationwide distribution of their molecular POC platform, bimx io, in the U.S.
- In March 2023, Lucira Health, a U.S.-based company that was acquired by Pfizer in April 2023, announced the launch of the first and only at-home COVID-19 and flu tests in the U.S., a test approved by the FDA under Emergency Use Authorization (EUA) for OTC usage at home and other nonlaboratory locations.
Key U.S. Point-of-Care Molecular Diagnostics Company Insights
Some of the key players operating in the U.S. point-of-care molecular diagnostics market include Abbott Laboratories; QIAGEN; F. Hoffman-La Roche Ltd; bioMerieux; and BD. Numerous key players are undertaking strategic initiatives such as expansion, product introductions, mergers, and acquisitions, while also focusing on increasing product reach in the U.S. Several market participants are investing in research and development initiatives, making the market susceptible to further growth.
Key U.S. Point-of-Care Molecular Diagnostics Companies:
- QIAGEN
- Danaher
- Thermo Fisher Scientific, Inc.
- BD
- F. Hoffman-La Roche AG
- Charles River Laboratories
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories, Inc.
- Hologic Inc.
- Agilent Technologies, Inc.
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Point-of-Care Molecular Diagnostics market.
By Test Location
- OTC
- POC
By Application Type
- Infectious Diseases
- HIV POC
- Clostridium difficile POC
- HBV POC
- Pneumonia or Streptococcus associated infections
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Flu POC
- HCV POC
- MRSA POC
- TB and drug-resistant TB POC
- HSV POC
- Other Infectious Diseases
- Oncology
- Hematology
- Prenatal Testing
- Endocrinology
- Other Applications
By Technology
- PCR-based
- Genetic Sequencing-based
- Hybridization-based
- Microarray-based
By End-use
- Decentralized Labs
- Hospitals
- Home-care
- Assisted Living Healthcare Facilities
- Other uses
Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/8417
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com